-
1
-
-
0036279836
-
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan
-
DOI 10.2174/1568009023333890
-
Mathijssen RH, Loos WJ, Verweij J, et al.: Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103-123, 2002 (Pubitemid 34625479)
-
(2002)
Current Cancer Drug Targets
, vol.2
, Issue.2
, pp. 103-123
-
-
Mathijssen, R.H.J.1
Loos, W.J.2
Verweij, J.3
Sparreboom, A.4
-
2
-
-
0028937909
-
The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs
-
Burke TG, Munshi CB, Mi Z, et al.: The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84:518-519, 1995
-
(1995)
J Pharm Sci
, vol.84
, pp. 518-519
-
-
Burke, T.G.1
Munshi, C.B.2
Mi, Z.3
-
3
-
-
81755171117
-
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
-
Park JR, Scott JR, Stewart CF, et al.: Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol 29:4351-4357, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 4351-4357
-
-
Park, J.R.1
Scott, J.R.2
Stewart, C.F.3
-
4
-
-
0037316914
-
A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors
-
Santana VM, Zamboni WC, Kirstein MN, et al.: A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633-640, 2003 (Pubitemid 36182595)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.2
, pp. 633-640
-
-
Santana, V.M.1
Zamboni, W.C.2
Kirstein, M.N.3
Tan, M.4
Liu, T.5
Gajjar, A.6
Houghton, P.J.7
Stewart, C.F.8
-
5
-
-
23044452535
-
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach
-
DOI 10.1200/JCO.2005.02.097
-
Santana VM, Furman WL, Billups CA, et al.: Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approch. J Clin Oncol 23:4039-4047, 2005 (Pubitemid 46211308)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4039-4047
-
-
Santana, V.M.1
Furman, W.L.2
Billups, C.A.3
Hoffer, F.4
Davidoff, A.M.5
Houghton, P.J.6
Stewart, C.F.7
-
6
-
-
79851510815
-
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma
-
De Ioris MA, Castellano A, Ilari I, et al.: Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer 47:572-578, 2011
-
(2011)
Eur J Cancer
, vol.47
, pp. 572-578
-
-
De Ioris, M.A.1
Castellano, A.2
Ilari, I.3
-
7
-
-
77956245879
-
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study
-
London WB, Frantz CN, Campbell LA, et al.: Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 28:3808-3815, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 3808-3815
-
-
London, W.B.1
Frantz, C.N.2
Campbell, L.A.3
-
8
-
-
0033927215
-
Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
-
Loos WJ, Gelderblom H, Sparreboom A, et al.: Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens. Clin Cancer Res 6:2685-2689, 2000 (Pubitemid 30482104)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.7
, pp. 2685-2689
-
-
Loos, W.J.1
Gelderblom, H.2
Sparreboom, A.3
Verweij, J.4
De Jonge, M.J.A.5
-
9
-
-
0037132703
-
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
-
Baker SD, Verweij J, Rowinsky EK, et al.: Role of body surface area in dosing investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002 (Pubitemid 36104633)
-
(2002)
Journal of the National Cancer Institute
, vol.94
, Issue.24
, pp. 1883-1888
-
-
Baker, S.D.1
Verweij, J.2
Rowinsky, E.K.3
Donehower, R.C.4
Schellens, J.H.M.5
Grochow, L.B.6
Sparreboom, A.7
-
10
-
-
79251496487
-
Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study
-
Engels FK, Loos WJ, van der Bol JM, et al.: Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study. Clin Cancer Res 17:353-362, 2011
-
(2011)
Clin Cancer Res
, vol.17
, pp. 353-362
-
-
Engels, F.K.1
Loos, W.J.2
Van Der Bol, J.M.3
-
11
-
-
0032979381
-
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines
-
DOI 10.1007/s002800050894
-
Zamboni WC, Houghton PJ, Hulstein JL, et al.: Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269-276, 1999 (Pubitemid 29075882)
-
(1999)
Cancer Chemotherapy and Pharmacology
, vol.43
, Issue.4
, pp. 269-276
-
-
Zamboni, W.C.1
Houghton, P.J.2
Hulstein, J.L.3
Kirstein, M.4
Walsh, J.5
Cheshire, P.J.6
Hanna, S.K.7
Danks, M.K.8
Stewart, C.F.9
-
12
-
-
34848904408
-
The relevance of microdialysis for clinical oncology
-
Kitzen JJ, Verweij J, Wiemer EA, et al.: The relevance of microdialysis for clinical oncology. Curr Clin Pharmacol 1:255-263, 2006
-
(2006)
Curr Clin Pharmacol
, vol.1
, pp. 255-263
-
-
Kitzen, J.J.1
Verweij, J.2
Wiemer, E.A.3
-
13
-
-
34848923745
-
Pitfalls of the application of microdialysis in clinical oncology: Controversial findings with docetaxel
-
DOI 10.1016/j.jpba.2007.07.023, PII S0731708507004372
-
Loos WJ, Zamboni WC, Engels FK, et al.: Pitfalls of the application of microdialysis in clinical oncology: Controversial findings with docetaxel. J Pharm Biomed Anal 45:288-294, 2007 (Pubitemid 47513426)
-
(2007)
Journal of Pharmaceutical and Biomedical Analysis
, vol.45
, Issue.2
, pp. 288-294
-
-
Loos, W.J.1
Zamboni, W.C.2
Engels, F.K.3
De Bruijn, P.4
Lam, M.H.5
De Wit, R.6
Verweij, J.7
Wiemer, E.A.C.8
-
14
-
-
30544438066
-
Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
-
DOI 10.1016/j.ejca.2005.08.035, PII S0959804905009299
-
Mathijssen RH, van Schaik RH: Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment. Eur J Cancer 42:141-148, 2006 (Pubitemid 43083482)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.2
, pp. 141-148
-
-
Mathijssen, R.H.J.1
Van Schaik, R.H.N.2
-
15
-
-
20044369878
-
Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol
-
DOI 10.1200/JCO.2005.11.036
-
Yamamoto N, Tamura T, Murakami H, et al.: Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 23:1061-1069, 2005 (Pubitemid 46202260)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.6
, pp. 1061-1069
-
-
Yamamoto, N.1
Tamura, T.2
Murakami, H.3
Shimoyama, T.4
Nokihara, H.5
Ueda, Y.6
Sekine, I.7
Kunitoh, H.8
Ohe, Y.9
Kodama, T.10
Shimizu, M.11
Nishio, K.12
Ishizuka, N.13
Saijo, N.14
-
16
-
-
80052009180
-
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
-
de Graan AJ, Teunissen SF, de Vos FY, et al.: Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 29:3240-3246, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 3240-3246
-
-
De Graan, A.J.1
Teunissen, S.F.2
De Vos, F.Y.3
-
17
-
-
0029743058
-
Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
-
Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2590-2611
-
-
Gurney, H.1
-
18
-
-
78049256742
-
Dose-escalation models for combination phase I trials in oncology
-
Hamberg P, Ratain MJ, Lesaffre E, et al.: Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 46:2870-2878, 2010
-
(2010)
Eur J Cancer
, vol.46
, pp. 2870-2878
-
-
Hamberg, P.1
Ratain, M.J.2
Lesaffre, E.3
|